In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.

Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.

It will come as no surprise that cross-border M&A is impacted by the world we live in, with geopolitical tensions, rising inflation and interest rates, currency fluctuations, and increased regulatory scrutiny all playing their part in making deals more challenging to execute.

Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.